HealthBiocon’s Breast Cancer Biosimilar Receives Positive EMA Opinion
Biocon Biologics' pertuzumab biosimilar, Pebrilzo, has received a positive opinion from the European Medicines Agency (EMA) committee. This endorsement brings Biocon closer to launching its breast cancer therapy in the European Union, marking a significant step forward in expanding access to affordable cancer treatment in Europe.
Business News India·




